α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease - Benskey - 2016 - Journal of Neurochemistry - Wiley Online Library

Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease, Molecular Brain

IJMS, Free Full-Text

HTRF Phospho-A-Synuclein Ser129 aggregation

Exosomal transmission of α-synuclein initiates Parkinson's disease-like pathology

Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease

α-Synuclein Aggregation in Treatment of Parkinson's Disease

Anti-Alpha-Synuclein Therapies in Parkinson's Disease - Practical Neurology

Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models

Cells, Free Full-Text

Models of α-synuclein aggregation in Parkinson's disease, Acta Neuropathologica Communications

Combating Parkinson's disease

ISIS Studying the influence of salts on α-synuclein aggregation, a hallmark of Parkinson's disease

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease